In November, 2003, we joined efforts with the American Society of Human Genetics (ASHG) in Los Angeles. Our meeting was a satellite of ASHG.
Personalized Isoniazid Dosing Based on Genotyping for Arylamine N-Acetyltransferase Type 2 (NAT2)
Submitted by:
Professor Uwe Fuhr,
University of Cologne |
The genetic basis of the acute side effects to the ACE inhibitor drugs-part I
Submitted by:
Dr Borzoo Nikpoor,
Drexel University College of Medicine |
Cost-Effectiveness of Pharmacogenomics
Submitted by:
Ms Stephanie Van Bebber,
University of California San Francisco |
Pharmacogenetics research in ethnically-identified populations
Submitted by:
Professor Charles Weijer,
Dalhousie University |
Pharmacogenetics based therapeutic recommendations in clinical practice
Submitted by:
Dr Julia Kirchheiner,
Institute of Clinical Pharmacology, Charité University Hospital |
Pharmacogenetics of antidepressants efficacy
Submitted by:
Dr alessandro serretti,
Vita-Salute university |
Pharmacogenomics of Drugs Affecting the Cardiovascular System
Submitted by:
Dr Gerard Siest,
Universite Henri Poincare Nancy I |
Impact of CYP2A6 Genetic Polymorphism in Tobacco-related Cancer Risk
Submitted by:
Professor Tetsuya Kamataki,
Hokkaido University Graduate School of Pharmaceutical Sciences |
The Human Haplotype Map
Submitted by:
Dr Francis Collins,
National Human Genome Research Institute |
ADRIS — A New in silico Approach to Collect, Store, Mine, and Visualize Pharmacogenetic Data
Submitted by:
Dr Felix Frueh,
TheraSTrat AG |
Pharmacogenomics, neuroplasticity and antidepressant research - beyond the monoamine hypothesis
Submitted by:
Dr Mitsuhiko Yamada,
Showa University Karasuyama Hospital |
Two Novel Haplotypes of CYP2D6 Gene with Impaired Drug Metabolizing Function in a Japanese Population
Submitted by:
Dr Hiroshi Yamazaki,
Hokkaido Univ. |
Two Novel Single Nucleotide Polymorphisms (SNPs) of the FMO3 Gene in Japanese
Submitted by:
Dr Masaki Fujieda,
Hokkaido University Graduate School of Pharmaceutical Sciences |
Effects of CYP2C9*3 allele on pharmacokinetics and pharmacodynamics of nateglinide in patients with type 2 diabetes mellitus
Submitted by:
Dr Shinya Uchida,
Hamamatsu University School of Medicine |
Phenotype-Genotype Association Studies and Individualized Drug Therapy: Advances and Setbacks
Submitted by:
Professor daniel w nebert,
Univ of Cincinnati Medical Center |
Pharmacogenetics of Opioid Analgesia: Interplay between Genes, Enzymes, Transporters and Receptors
Submitted by:
Professor Andrew Somogyi,
University of Adelaide |
Effect of Dopaminergic and Serotonergic Gene Polymorphisms on Antipsychotic Response to Risperidone
Submitted by:
Dr Masashi Ikeda,
Nagoya University Graduate School of Medicine |
Identification of Chemotherapy Response Loci Using a novel Ex Vivo Strategy
Submitted by:
Dr James Watters Watters,
Washington University |
An experimental therapeutic approach to genetically-based obesity: Leptin replacement therapy resolves morbis obesity, hypogonadism and diabetes mellitus in leptin-deficient adults
Submitted by:
Dr Bulent Yildiz,
UCLA |
Altered pharmacokinetics and excessive hypotensive effect of candesartan in a patient with the CYP2C9*1/*3 genotype
Submitted by:
Professor Kyoichi Ohashi,
Hamamatsu University School of Medicine |
Dopamine transporter density is not altered in naïve schizophrenia patients after acute antipsychotic treatment assessed with [99mTc] TRODAT-1 SPECT
Submitted by:
Dr Mei-Chun Hsiao,
Chang-Gung medical center |
Pharmacogenetics as a predictive tool for a safer and more effective drug therapy - the state of the art
Submitted by:
Professor Magnus Ingelman-Sundberg,
Karolinska Institutet |
Application of genomics tools to drug development
Submitted by:
Dr Olivier Grenet Grenet,
NOVARTIS |
Development of a genetic test for the prediction of clozapine response
Submitted by:
Dr Christian Oberkanins,
ViennaLab Labordiagnostika |
Pharmacogenetics of Cardiovascular Risk Therapy
Submitted by:
Dr Ronald Krauss,
CHORI |
Pharmacogenetics of Phase II Drug-Metabolizing Enzymes
Submitted by:
Dr Richard Weinshilboum,
Mayo Clinic |
Five Decades of Pharmacogenetics - The Lessons and the Problems
Submitted by:
Professor Urs A. Meyer,
University of Basel |
Pharmacogenetic approaches to tardive dyskinesia
Submitted by:
Professor Bernard Lerer,
Hadassah - Hebrew University |
Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes
Submitted by:
Dr Norio Yasui-Furukori,
Hirosaki University School of Medicine |
Pharmacogenetic study of fluvoxamine response in major depression using 5HTT, 5HT2A and 5HT3A gene polymorphisms
Submitted by:
Dr Tsuyoshi Kitajima,
Fujita Health University School of Medicine |
The relationship of the serotonin transporter gene promoter region polymorphism to antidepressant response and adverse effects of paroxetine in Japanese depressive patients.
Submitted by:
Dr Genta Hirokane,
Shiga University of Medical Science |
Integrating genomics, proteomics, and bioinformatics for cancer drug discovery.
Submitted by:
Dr John Weinstein,
National Cancer Institute |
PolyMAPr: A Program For Automated Database Mining And Polymorphism Annotation
Submitted by:
Dr Robert Freimuth,
Washington University School of Medicine |
Clinical Impact of Genetic Polymorphism in the Cytochrome P450 CYP2C9 on the Management of Warfarin in Chinese Patients---An Interim Analysis
Submitted by:
Professor Vivian Lee,
The Chinese University of Hong Kong |
Paroxetine steady-state plasma concentrations in relation to CYP2D6 genotypes in Japanese psychiatric patients
Submitted by:
Dr Mikito Ueda,
Shiga University of Medical Science |
Pharmacogenomic study on the mechanism of adverse reaction of clozapine
Submitted by:
Professor Sung Vin Yim ,
Kyunghee University |
The relationship between plasma concentration of fluvoxamine and its clinical efficacy in depressed patients
Submitted by:
Dr Yutaro Suzuki,
Niigata University Graduate School of Medical and Dental Sciences |
The effects of 5-HT1A receptor gene polymorphism on clinical response to fluvoxamine
Submitted by:
Dr Yutaro Suzuki,
Niigata University Graduate School of Medical and Dental Sciences |
Effects of dosage and CYP2D6 mutated allele on plasma concentration of paroxetine.
Submitted by:
Dr Kazushi Sawamura,
Niigata University Graduate School of Medical and Dental Sciences |
The Effect of Dosage, Cytochrome P450 (CYP) 2D6 gene polymorphism, Smoking on Plasma Concentration of Fluvoxamine.
Submitted by:
Dr Takuro Sugai,
Niigata University Graduate School of Medical and Dental Sciences |
Identification and Integration of Diverse Genomic Signals: Building Neuroinformatics Tools for Pharmacogenomics Applications
Submitted by:
Dr Kristopher Irizarry,
UCLA |
DOPAMINE RECEPTOR DRD2 GENOTYPE AND SMOKING CESSATION OUTCOME FOLLOWING TREATMENT WITH BUPROPION SR
Submitted by:
Dr Huijun Ring,
SRI International |
